GSK’s lung cancer drug receives US Breakthrough Therapy Designation
Drug gets US regulatory fast-trackSecond-phase trials planned for H2Significant need for new treatmentsGlobal biopharma company GSK (GSK) said it had received US Breakthrough Therapy Designation for its investigational antibody-drug to treat patients with extensive-stage small-cell lung cancer.GSK shares dipped 13p or 0.8% to £15.86 on a weak day for UK stocks generally. WHAT DOES IT MEAN?